Menu
Home
About Us
Who We Are
Purpose & Values
Board
Partners
Distributors
Compliance
Careers
Technology
Our Solution
Technology Introduction
Platform Technology
Publications
Image Gallery
Webinars
FAQ
Products
Our Products
InVivage
ViewnVivo
Customisation
Pipeline
Investor
Investor Overview
ASX Announcements
Reports
Share Price Information
Financial Calendar
Media Coverage
Sustainability
Share Registry
Investor Alerts
Media
News
Social Media Feed
Blog / Newsletter
Contact
Contact
Select Category
Clinical Research
Oral cancer diagnosis and surgical margin
Brain cancer
General surgery
Cervical assessment
Gastrointestinal assessment
Life Sciences Research
Cell viability
Live antibody labelling
Intraoperative surgery and tumour margin delineation
Blood vessel, perfusion, and barrier function
Live microflora imaging
Nano particle and drug delivery
Proof of concept in live models
Recent Posts
Optiscan featured in The West Australian
Optiscan featured in The West Australian
Entitlement Offer Results and Shortfall Announcement
InVivage study with Melbourne Dental School published in Frontiers of Oncology
Optiscan featured in The West Australian
Archives
September 2023
August 2023
July 2023
June 2023
May 2023
April 2023
March 2023
February 2023
January 2023
November 2022
September 2022
February 2022
May 2021
March 2021
January 2021
December 2020
Categories
Announcements
Blood vessel, perfusion, and barrier function
Brain cancer
Broker Research
Cell viability
Cervical assessment
Gastrointestinal assessment
General surgery
Intraoperative surgery and tumour margin delineation
Live antibody labelling
Live microflora imaging
Nano particle and drug delivery
Optiscan news
Oral cancer diagnosis and surgical margin
Proof of concept in live models
Uncategorized
Veterinary
Optiscan Technology Feature
September 27th, 2022 by Optiscan
Read More
Optiscan CEO Prof. Camile Farah published in Medical Forum September 2022
September 9th, 2022 by Optiscan
Read More
1
Back to All Publications
